Hospital admissions for hemolytic disease of the newborn in the state of Piaui, between 2014 and 2019
Keywords:Fetal erythroblastosis; Brazil; Public health.
Hemolytic Disease of the Fetus and Newborn (HDFN) is caused by maternal alloimmunization to erythrocyte antigens, in which fetal and neonatal erythrocytes are destroyed, leading to fetal hemolysis and other injuries that must be monitored by a multidisciplinary team, which demands expenses for the public health system. This study aimed to describe hospitalizations by HDFN in the state of Piauí in the period between 2014 and 2019. It is a qualitative and quantitative descriptive study that used secondary data to describe hospitalizations by HDFN, in the state of Piauí between the years 2014 to 2019 During the study period, there were a total of 70 admissions due to HDFN, which represents only 0.40% of admissions across the country in the same year. The average stay of these hospitalizations is 5.4 days, while the average cost is R$ 506.24. In Brazil, there were 64 deaths in relation to these admissions and the period in question, none of which occurred in Piauí. It is clear, then, that there is a need to carry out further studies on this topic to gain knowledge of the real nature of HDFN cases in the state of Piauí. It is not possible to infer whether there is underreporting of cases or if in fact there is a smaller number of occurrences. In addition, in 2018 there was a dissonant increase in the number of cases on the coast, and there are no records in the literature to help justify this increase.
Baldwin, K. M., & Spears, M. J. (2019). Improving the patient experience and decreasing patient anxiety with nursing bedside report. Clinical Nurse Specialist, 33(2), 82-89.
De Haas, M., Thurik, F. F., Koelewijn, J. M., & Van der Schoot, C. E. (2015). Haemolytic disease of the fetus and newborn. Vox sanguinis, 109(2), 99-113.
Departamento de Informática do SUS (DATASUS). Doença hemolítica do feto e do recém-nascido – Morbidade hospitalar no Sistema de Informações hospitalares do SUS (SIH/SUS). http://tabnet.datasus.gov.br/cgi/deftohtm.exe?sih/cnv/nipi.def
FIOCRUZ. (2018). Conferências Fiocruz Brasília, II Encontro da ReDAPTS - ATS para o SUS: Experiências e Desafios para Análise Econômica. http://conferencias.brasilia.fiocruz.br/index.php/ats/ReDAPTS/paper/view/446
Iberahim, S., Aizuddin, M. J., Abd Kadir, N., Rameli, N., Adzahar, S., Noor, N. H. M., & Abdullah, W. Z. (2020). Hemolytic Disease of Fetus and Newborn in a primigravida with multiple alloantibodies involving anti-Jka and anti-E: A case report. Oman medical journal, 35(6), e206.
Kang, W., Yuan, X., Zhang, Y., Song, J., Xu, F., Liu, D., ... & Zhu, C. (2020). Early prediction of adverse outcomes in infants with acute bilirubin encephalopathy. Annals of Clinical and Translational Neurology, 7(7), 1141-1147.
Keir, A., Agpalo, M., Lieberman, L., & Callum, J. (2015). How to use: the direct antiglobulin test in newborns. Archives of Disease in Childhood-Education and Practice, 100(4), 198-203.
Kristinsdottir, T., Kjartansson, S., Hardardottir, H., Jonsson, T., & Halldorsdottir, A. M. (2016). Antibodies bound to neonatal erythrocytes; Causes and Clinical Consequences-Cases analyzed at the Blood Bank 2005-2012. Laeknabladid, 102(7-8), 326–331.
Lin, M., Liu, M., Zhang, S., Chen, C., & Wang, J. (2021). Different Types of Minor Blood Group Incompatibility Causing Haemolytic Disease of Neonates in one of the National Children's Medical Centre in China. Journal of Blood Medicine, 12, 497.
Lobato, G., Reichenheim, M. E., & Coeli, C. M. (2008). Sistema de informações hospitalares do sistema único de saúde (SIH-SUS): uma avaliação preliminar do seu desempenho no monitoramento da doença hemolítica perinatal Rh (D). Cadernos de Saúde Pública, 24, 606-614.
Moise, K. J. (2002). Management of rhesus alloimmunization in pregnancy. Obstetrics & Gynecology, 100(3), 600-611.
Moise, K. J. (2008). Fetal anemia due to non-Rhesus-D red-cell alloimmunization. In Seminars in fetal and neonatal medicine, 13(4), 207-214.
Morris, E. A., & Stark, A. R. (2019). Anemia in the Nursery: When to Observe, When to Treat, and When to Refer. In Common Problems in the Newborn Nursery, 89-98. Springer, Cham.
Myle, A. K., & Al-Khattabi, G. H. (2021). Hemolytic Disease of the Newborn: A Review of Current Trends and Prospects. Pediatric Health, Medicine and Therapeutics, 12, 491.
Pegoraro, V., Urbinati, D., Visser, G. H., Di Renzo, G. C., Zipursky, A., Stotler, B. A., & Spitalnik, S. L. (2020). Hemolytic disease of the fetus and newborn due to Rh (D) incompatibility: A preventable disease that still produces significant morbidity and mortality in children. PloS one, 15(7), e0235807.
Ree, I. M., Smits-Wintjens, V. E., van der Bom, J. G., van Klink, J. M., Oepkes, D., & Lopriore, E. (2017). Neonatal management and outcome in alloimmune hemolytic disease. Expert review of hematology, 10(7), 607-616.
Seidl, V. (2013) Doença hemolítica perinatal: fatores de risco e abordagem terepêutica. Fundação Oswaldo Cruz, 201. https://www.arca.fiocruz.br/bitstream/icict/8313/2/69594.pdf
Tyndall, C., Cuzzilla, R., & Kane, S. C. (2020). The rhesus incompatible pregnancy and its consequences for affected fetuses and neonates. Transfusion and Apheresis Science, 59(5).
Urbaniak, S. J., & Greiss, M. A. (2000). RhD haemolytic disease of the fetus and the newborn. Blood reviews, 14(1), 44-61.
Xie, X., Fu, Q., Bao, Z., Zhang, Y., & Zhou, D. (2020). Clinical value of different anti-D immunoglobulin strategies for preventing Rh hemolytic disease of the fetus and newborn: A network meta-analysis. PloS one, 15(3), e0230073.
Zwiers, C., van Kamp, I., Oepkes, D., & Lopriore, E. (2017). Intrauterine transfusion and non-invasive treatment options for hemolytic disease of the fetus and newborn–review on current management and outcome. Expert review of hematology, 10(4), 337-344.
How to Cite
Copyright (c) 2021 Eduarda Estela Macedo; Clara Bittencourt Lima; Allan Victor Damasceno Coelho; Rubens Renato de Sousa Carmo; Carlos Leandro da Cruz Nascimento; Aluydio Bessa Amaral; Antônio Thomaz Oliveira
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.